Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
United Therapeutics's Business Segments
United Therapeutics's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
9
Largest Segment
Tyvaso
Total Revenue
$ 783
Regions Reported
1
Revenue Share by Reportable Segment - FY
- Tyvaso0%
- Tyvaso DPI83.9%
- Orenitram33.4%
- Nebulized Tyvaso32.3%
- Remodulin32.3%
- Unituxin15.2%
- Non-US11.1%
- Product and Service, Other1.5%
- Adcirca1.2%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Tyvaso | $ 910 | - |
| Tyvaso DPI | $ 657 | 83.9% |
| Orenitram | $ 261 | 33.4% |
6 more segments available
Sign in to unlock the full United Therapeutics dataset.
Revenue Share by Region - FY
- Non-US4.8%
Revenue by Geographic Region - FY
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Non-US | $ 37 | 4.8% |
Revenue by Product & Service Category - FY
- Tyvaso56.7%
- Tyvaso DPI42.3%
- Orenitram17.4%
- Nebulized Tyvaso16.3%
- Remodulin16.2%
- Unituxin6.9%
- Product and Service, Other0.7%
- Adcirca0.4%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Tyvaso | $ 443 | 56.7% |
| Tyvaso DPI | $ 330 | 42.3% |
| Orenitram | $ 136 | 17.4% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
5 more categories available
Sign in to unlock the full United Therapeutics dataset.
Annual Results
Revenue Share by Reportable Segment - FY
- Tyvaso0%
- Tyvaso DPI83.9%
- Orenitram33.4%
- Nebulized Tyvaso32.3%
- Remodulin32.3%
- Unituxin15.2%
- Non-US11.1%
- Product and Service, Other1.5%
- Adcirca1.2%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Tyvaso | $ 910 | - |
| Tyvaso DPI | $ 657 | 83.9% |
| Orenitram | $ 261 | 33.4% |
6 more segments available
Sign in to unlock the full United Therapeutics dataset.
Description of United Therapeutics
United Therapeutics Corporation is a biotechnology company headquartered in Silver Spring, Maryland. The company is focused on the development, manufacturing, and commercialization of innovative therapies to treat rare disorders and life-threatening diseases. It was founded in 1996 by Martine Rothblatt.
The company has a diverse portfolio of products that includes both therapeutic drugs and wearable technology for remote patient monitoring. It conducts extensive research in pulmonary hypertension (PH), neuroblastoma, and hematologic cancers.
United Therapeutics operates in several business segments: commercial, research and development, and manufacturing. The company has a strong global presence and has offices and facilities in the United States, Europe, and Asia.
One of the key drugs developed by United Therapeutics is called Remodulin, which is used to treat pulmonary arterial hypertension (PAH). PAH is a rare and life-threatening condition that occurs when the blood vessels in the lungs become narrow, leading to high blood pressure and eventual heart failure. Remodulin is administered through a small pump that is connected to a catheter in the patient’s chest.
Another drug developed by United Therapeutics is called Tyvaso, which is also used to treat PAH. Tyvaso is an inhaled medication that is delivered through a portable device.
In addition to developing therapies for PAH, United Therapeutics is actively researching treatments for neuroblastoma, a rare cancer that affects children, as well as hematologic cancers such as leukemia and lymphoma.
The company also offers wearable technology for remote patient monitoring. One of the most notable products is the TytoCare device, which allows patients to perform basic medical exams at home and share the data with their healthcare providers.
United Therapeutics has received numerous accolades for its contributions to the biotech industry. In 2017, the company was recognized as one of the world’s most innovative companies by Forbes magazine.
Overall, United Therapeutics Corporation is dedicated to improving the lives of patients with rare and life-threatening diseases through innovative research, manufacturing, and commercialization of high-quality therapies and medical devices.
The company has a diverse portfolio of products that includes both therapeutic drugs and wearable technology for remote patient monitoring. It conducts extensive research in pulmonary hypertension (PH), neuroblastoma, and hematologic cancers.
United Therapeutics operates in several business segments: commercial, research and development, and manufacturing. The company has a strong global presence and has offices and facilities in the United States, Europe, and Asia.
One of the key drugs developed by United Therapeutics is called Remodulin, which is used to treat pulmonary arterial hypertension (PAH). PAH is a rare and life-threatening condition that occurs when the blood vessels in the lungs become narrow, leading to high blood pressure and eventual heart failure. Remodulin is administered through a small pump that is connected to a catheter in the patient’s chest.
Another drug developed by United Therapeutics is called Tyvaso, which is also used to treat PAH. Tyvaso is an inhaled medication that is delivered through a portable device.
In addition to developing therapies for PAH, United Therapeutics is actively researching treatments for neuroblastoma, a rare cancer that affects children, as well as hematologic cancers such as leukemia and lymphoma.
The company also offers wearable technology for remote patient monitoring. One of the most notable products is the TytoCare device, which allows patients to perform basic medical exams at home and share the data with their healthcare providers.
United Therapeutics has received numerous accolades for its contributions to the biotech industry. In 2017, the company was recognized as one of the world’s most innovative companies by Forbes magazine.
Overall, United Therapeutics Corporation is dedicated to improving the lives of patients with rare and life-threatening diseases through innovative research, manufacturing, and commercialization of high-quality therapies and medical devices.
United Therapeutics Corporation is a pioneering healthcare company specializing in the development and commercialization of innovative therapies for patients with rare diseases, particularly those with significant unmet medical needs. The companys diverse product portfolio and services are organized across various therapeutic segments, focusing primarily on pulmonary hypertension, pediatric oncology, and organ transplantation.
1. Pulmonary Hypertension
Pulmonary hypertension (PH) is a serious condition characterized by high blood pressure in the pulmonary arteries, leading to symptoms such as breathlessness, fatigue, and impaired exercise capacity. United Therapeutics is actively engaged in providing a multitude of therapies aimed at managing this debilitating disease:
- Tyvaso (treprostinil) Inhalation Solution: Designed for patients with pulmonary arterial hypertension (PAH), Tyvaso is administered via a nebulizer, allowing for direct delivery to the lungs. Patients can use this medication multiple times a day to enhance their breathing and increase their ability to engage in physical activity.
- Remodulin (treprostinil) Injection: This injectable formulation offers an alternative route of administration for PAH patients who may benefit from continuous infusion via a subcutaneous or intravenous pump. Remodulin is crucial for managing the symptoms of PAH and improving the quality of life.
- Orenitram (treprostinil) Extended-Release Tablets: Orenitram provides a more convenient oral delivery option for patients dealing with PAH. These extended-release tablets are designed for once-daily dosing and are effective in managing disease symptoms.
- Adcirca (tadalafil): This oral therapy acts as a phosphodiesterase-5 inhibitor, working to relax the blood vessels in the lungs, allowing for better blood flow and oxygenation. It is another option available for patients experiencing PAH.
Neuroblastoma
United Therapeutics is also committed to developing targeted therapies for childhood cancers, particularly neuroblastoma, which is a malignancy that primarily affects young children. Its leading therapeutic agent for this indication is:
- Unituxin (dinutuximab): This monoclonal antibody treatment is specifically designed for patients with high-risk neuroblastoma. It plays a critical role in the post-chemotherapy treatment process, enhancing the immune systems ability to target and destroy cancer cells. Unituxin is used in conjunction with other therapies to improve overall treatment outcomes for these vulnerable patients.
Organ Transplantation
The company recognizes the challenges faced by organ transplant recipients, who often require lifelong immunosuppression to prevent transplant rejection. United Therapeutics offers:
- Hizentra (Immune Globulin Intravenous ): While primarily used for patients with primary immunodeficiency disorders, Hizentras role in the transplantation community focuses on helping to maintain a balanced immune response post-transplant. Its administration is important for minimizing the risk of infections and other complications associated with the need for immunosuppression.
Support Services
In addition to its extensive product offerings, United Therapeutics provides a range of support services designed to enhance patient care and navigate the challenges associated with rare diseases:
- Therapy Management Programs: These programs are designed to support patients in managing their treatment regimens, improving adherence, and maximizing therapeutic outcomes.
- Reimbursement Assistance: Understanding the complexities of healthcare reimbursement, United Therapeutics offers assistance programs to help patients access the treatments they need without undue financial burden.
- Clinical Trial Recruitment Assistance: The company actively engages in research to discover new therapies. It assists patients in finding suitable clinical trials that may be beneficial, providing opportunities for access to cutting-edge treatments.
Through its commitment to innovation and patient support, United Therapeutics Corporation is at the forefront of developing solutions for complex and often life-threatening conditions, striving to improve the lives of those affected by rare diseases.
1. Pulmonary Hypertension
Pulmonary hypertension (PH) is a serious condition characterized by high blood pressure in the pulmonary arteries, leading to symptoms such as breathlessness, fatigue, and impaired exercise capacity. United Therapeutics is actively engaged in providing a multitude of therapies aimed at managing this debilitating disease:
- Tyvaso (treprostinil) Inhalation Solution: Designed for patients with pulmonary arterial hypertension (PAH), Tyvaso is administered via a nebulizer, allowing for direct delivery to the lungs. Patients can use this medication multiple times a day to enhance their breathing and increase their ability to engage in physical activity.
- Remodulin (treprostinil) Injection: This injectable formulation offers an alternative route of administration for PAH patients who may benefit from continuous infusion via a subcutaneous or intravenous pump. Remodulin is crucial for managing the symptoms of PAH and improving the quality of life.
- Orenitram (treprostinil) Extended-Release Tablets: Orenitram provides a more convenient oral delivery option for patients dealing with PAH. These extended-release tablets are designed for once-daily dosing and are effective in managing disease symptoms.
- Adcirca (tadalafil): This oral therapy acts as a phosphodiesterase-5 inhibitor, working to relax the blood vessels in the lungs, allowing for better blood flow and oxygenation. It is another option available for patients experiencing PAH.
Neuroblastoma
United Therapeutics is also committed to developing targeted therapies for childhood cancers, particularly neuroblastoma, which is a malignancy that primarily affects young children. Its leading therapeutic agent for this indication is:
- Unituxin (dinutuximab): This monoclonal antibody treatment is specifically designed for patients with high-risk neuroblastoma. It plays a critical role in the post-chemotherapy treatment process, enhancing the immune systems ability to target and destroy cancer cells. Unituxin is used in conjunction with other therapies to improve overall treatment outcomes for these vulnerable patients.
Organ Transplantation
The company recognizes the challenges faced by organ transplant recipients, who often require lifelong immunosuppression to prevent transplant rejection. United Therapeutics offers:
- Hizentra (Immune Globulin Intravenous ): While primarily used for patients with primary immunodeficiency disorders, Hizentras role in the transplantation community focuses on helping to maintain a balanced immune response post-transplant. Its administration is important for minimizing the risk of infections and other complications associated with the need for immunosuppression.
Support Services
In addition to its extensive product offerings, United Therapeutics provides a range of support services designed to enhance patient care and navigate the challenges associated with rare diseases:
- Therapy Management Programs: These programs are designed to support patients in managing their treatment regimens, improving adherence, and maximizing therapeutic outcomes.
- Reimbursement Assistance: Understanding the complexities of healthcare reimbursement, United Therapeutics offers assistance programs to help patients access the treatments they need without undue financial burden.
- Clinical Trial Recruitment Assistance: The company actively engages in research to discover new therapies. It assists patients in finding suitable clinical trials that may be beneficial, providing opportunities for access to cutting-edge treatments.
Through its commitment to innovation and patient support, United Therapeutics Corporation is at the forefront of developing solutions for complex and often life-threatening conditions, striving to improve the lives of those affected by rare diseases.